High ALC (N= 82) | Low ALC (N= 36) | P-value | |
---|---|---|---|
Age | |||
< 60 vs. ≥ 60 years | 51/31 | 21/15 | 0.692 |
Gender | |||
Male vs. Female | 55/27 | 24/12 | 0.966 |
Performance status | |||
0-1 vs. 2-4 | 74/8 | 30/6 | 0.355 |
B symptom | |||
Present vs. Absent | 21/61 | 11/25 | 0.578 |
Stage | |||
1-2 vs. 3-4 | 31/51 | 8/28 | 0.098 |
Extranodal involvement | |||
0-1 vs. ≥ 2 | 62/20 | 21/15 | 0.059 |
Bone marrow involvement | |||
Positive vs. Negative | 21/61 | 12/24 | 0.389 |
LDH | |||
Normal vs. Elevated | 45/37 | 12/24 | 0.031 |
IPI | |||
L, LI vs. HI, H | 57/25 | 18/18 | 0.043 |
PIT | |||
Group 1-2 vs. 3-4 | 57/25 | 16/20 | 0.010 |
CR | |||
CR vs. non-CR | 42/37 | 14/12 | 0.952 |
Response (≥ PR) | |||
Responder vs. Non-responder | 61/18 | 17/9 | 0.231 |
TRM during the 1st line chemotherapy | |||
Yes vs. No | 4/78 | 9/27 | 0.003 |
Cycles of 1st line Chemotherapy | |||
Median, range | 6 (1-8) | 3 (1-9) | 0.007 |